See today's BioWorld Science
To read the full story, subscribe or sign in.
Infection

JNJ-9117, a potent pan-genotype HEV replication inhibitor with promising antiviral profile

June 12, 2024
At last week’s EASL meeting, Janssen Pharmaceutica NV disclosed the discovery and preclinical evaluation of a novel pan-genotypic hepatitis E virus (HEV) replication inhibitor, JNJ-64779117 (JNJ-9117).
BioWorld Science Conferences New compound International Liver Congress Infection